Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 August 2014 | By Alexander Gaffney, RAC,
US regulators have finally released the text of a 2009 industry proposal that is set to form the basis of discussion at an upcoming meeting on whether companies should be allowed to "reserve" drug names for late-stage investigational drugs.
As Focus reported in July 2014, FDA recently issued a notice indicating that it was exploring allowing companies to reserve drug names.
Because drug names are dispensed on a first-come, first-served basis, companies often generate several proposed names for a drug at the time of filing. Drug names aren't approved, however, until the time that the drug itself is. And because a company has no idea of the names other companies have requested from FDA, its proposed name could be knocked out of commission by a product that wasn't even approved at the time of its submission—what FDA calls an "intervening entry into the US market."
Complicating matters further, companies generally seek worldwide approval for their drugs. If a product has been approved under one name in most regions, but fails to get approval for that same name in the US, that can potentially cause confusion for healthcare providers and patients alike, who may be familiar with a drug's other name.
Accordingly, FDA and members of industry have been interested in building a more predictable mechanism for approving new drug names.
Most notably, in 2009 the US pharmaceutical trade group PhRMA sent FDA a working draft of a guidance document that outlined its then-preferred system for approving drug names. In FDA's July 2014 meeting notice, the agency said PhRMA's guidance would be one of the primary focuses of its meeting, and implied it might potentially be used as the basis for future agency guidance.
But since FDA first posted its meeting notice, industry analysts have been missing one important detail: PhRMA's guidance. Requests by Focus to obtain the guidance were declined by PhRMA, which said in a statement that what it had submitted in 2009 was "a bit outdated," and that it would not be making it "available publicly" as a result.
But after several rounds of requests, FDA has finally posted the document to its public docket, affording the public a glimpse at what could become the basis for the future drug name reservation system.
As PhRMA's guidance explains, "the lack of early final approval of proprietary names gives rise to a system that is time and resource intensive for both the Agency and the applicant, and creates unnecessary delays and uncertainty in the approval process."
What the trade group would like to see instead is a voluntary system in which sponsors could reserve a drug name once a product has cleared Phase II clinical testing. At present, companies can request a name at this stage, but can only receive "tentative" approval for the name—not binding approval.
To guard against name hoarding, PhRMA's guidance anticipates that any names not used within 18 months of an initial request will then be available for use by other companies, or subject to an 18-month extension that would also make the drug name and release date available on FDA's website. Withdrawn names can be re-submitted to the agency, but can no longer be reserved.
While this system might otherwise release confidential commercial information (CCI), because the system is voluntary, it should avoid potential issues, PhRMA said.
Notably, the system calls for FDA to publish all proprietary names on FDA's website, along with the date the name reservation is expected to end. FDA "will not disclose the name of the applicant" or any other details about the drug, according to the guidance.
Focus reached out to PhRMA for comment on the guidance, but did not receive a response by the time this article was first published.
PhRMA Guidance
Tags: PhRMA, Draft Guidance, Drug Naming, Drug Name, Drug Name Reservation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.